NASDAQ: SAVACassava Sciences Inc Stock
$20.74+0.19 (+0.92%)
Updated Apr 24, 2024
SAVA Price
$20.74
Fair Value Price
$2.89
Market Cap
$896.49M
52 Week Low
$12.32
52 Week High
$32.10
P/E
-8.94x
P/B
6.52x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$97.22M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.1
Operating Cash Flow
-$82M
Beta
1.3
Next Earnings
Apr 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SAVA Overview
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SAVA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SAVA ($20.74) is overvalued by 617.93% relative to our estimate of its Fair Value price of $2.89 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SAVA ($20.74) is not significantly undervalued (617.93%) relative to our estimate of its Fair Value price of $2.89 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SAVA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SAVA due diligence checks available for Premium users.
Be the first to know about important SAVA news, forecast changes, insider trades & much more!
SAVA News
Valuation
SAVA fair value
Fair Value of SAVA stock based on Discounted Cash Flow (DCF)
Price
$20.74
Fair Value
$2.89
Overvalued by
617.93%
SAVA ($20.74) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SAVA ($20.74) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SAVA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SAVA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.94x
Industry
15.69x
Market
41.27x
SAVA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.52x
Industry
5.86x
SAVA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SAVA's financial health
Profit margin
Revenue
$0.0
Net Income
-$20.9M
Profit Margin
0%
SAVA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$151.7M
Liabilities
$14.2M
Debt to equity
0.1
SAVA's short-term assets ($129.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SAVA's short-term assets ($129.63M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SAVA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SAVA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.3M
Investing
-$41.0k
Financing
$1.1M
SAVA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SAVA vs Biotech Stocks
Cassava Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.